1583: The Biotech Transforming Disease Detection and Monitoring Drug Response

As regular listeners will know, I am fascinated by our new proactive rather than reactive approach to healthcare, and the role tech plays in that change. We already monitor our steps, heart rate, calorie intake and can even have an ECG machine on hand. Today, Caroline Loew, CEO of Glympse, joins me in a conversation about biotech innovation.

Caroline shares their mission to detect diseases earlier and help develop better therapies so that people don't become patients and return to health faster. We discuss their novel technology: activity-based biosensors that are bioengineered and tunable to any protease-mediated disease.

I also learn how Glympse's technology can measure and predict the trajectory of a disease in a non-invasive, real-time, functional readout that is clinically actionable.

Glympse Bio is pioneering an in vivo sensing technology dedicated to transforming disease monitoring. The company has built a product engine enabling the rapid development of tunable and bioengineered activity sensors for multiple indications, including fibrosis, cancer, immunology, and infectious diseases.

The technology has been validated in 10 different diseases using multiple delivery methods and a broad range of analytical readouts. Glympse aims to improve healthcare globally by serving the needs of patients, clinicians, researchers, drug developers, and payors to help advance the science and our understanding of human diseases.